Table 7.
Adverse events other than cytopenias.
| Adverse Events Before and/or during Eltrombopag Treatment | |
|---|---|
| CRS | |
| Patients, n/N (%) | 32/38 (84.2) |
| Time from CAR-T cell infusion to onset, days | 2 (1, 4) |
| Grade | 2 (1, 2) |
| Time from onset to resolution, days | 5 (4, 9) |
| ICANS | |
| Patients, n/N (%) | 21/38 (55.3) |
| Time from CAR-T cell infusion to onset, days | 6 (5, 8) |
| Grade | 2 (2, 3) |
| Time from onset to resolution, days | 4 (2, 7) |
| Infection, n/N (%) | 19/38 (50.0) |
| Fatal, n/N (%) | 6/19 (26.3) |
| Toxicities during eltrombopag treatment | |
| Patients with toxicities requiring eltrombopag suspension, n/N (%) | 1/38 (2.6) |
| Type of toxicity | |
| Cholestasis, transaminitis *, n/N (%) | 1/1 (100) |
| Patients with other toxicities not requiring hospitalization or suspension, n/N (%) | 1/38 (2.6) |
| Type of toxicity | |
| Hyperbilirubinemia †, n/N (%) | 1/1 (100) |
Results are median (IQR), except otherwise indicated. * One episode; eltrombopag was resumed when toxicity was resolved. † One episode; eltrombopag dose was lowered to 100 mg/day until resolution. CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; IQR, interquartile range.